GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Merck Sharp & Dohme (MSD)

Status: Terminated

Conditions: Papillomavirus Infections

Study type: Observational

Funder types: Industry

Identifiers

NCT01355003

V501-077

Details and patient eligibility

About

This study will collect safety information on the use of GARDASIL™ in the Philippines.

Enrollment: 1,080 patients

Sex: All

Ages: 9 to 46 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Received GARDASIL™

Trial design

1,080 participants in 1 patient group

All Participants

Description:

Participants who were vaccinated with GARDASIL™ by their physician